2 studies found for:    19917835 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Study of Neoadjuvant Vemurafenib for BRAF Mutant Melanoma and Palpable Lymph Node Metastasis
Condition: Melanoma
Intervention: Drug: Vemurafenib
2 Recruiting Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Biological: Ofatumumab;   Biological: Ofatumumab plus Dacarbazine

Indicates status has not been verified in more than two years